Ovid Therapeutics Inc. (OVID)
- Sector
- Healthcare
- Industry
- Biotechnology
- Last price
- $2.45
- As of
Kresmion compiles this page from OVID's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.
Ovid Therapeutics Inc. (OVID): 5 institutional managers tracked by Kresmion reported non-option positions in their 2026Q2 Form 13F filings, and the most recent SEC filing on record for the company is a Form 8-K filed 2026-08-13.
See the full OVID dossier
Price with insider and filing markers, who is positioning, fundamentals and peers for OVID on one page. Preview it with sample data, then open it live with a free account.
Preview the OVID dossierActive events for OVID
- mediumEarnings above estimates
Q2-2026: Beat consensus by 35.2%, EPS $-0.08 vs $-0.1234 estimate
- high13F: large increase
CITADEL ADVISORS LLC added +58% to OVID (2026Q2)
- high13F: large reduction
MILLENNIUM MANAGEMENT LLC cut 98% of OVID (2026Q2)
- high13F: large reduction
RENAISSANCE TECHNOLOGIES LLC cut 90% of OVID (2026Q2)
- medium13F: new position
D. E. Shaw & Co., Inc. new position in OVID
FREE, NO ACCOUNT
Every event on OVID, as it fires
You are seeing 5 of 10 events recorded on OVID since 2026-05-17.
The five above landed across 2 days. The other 5 were recorded on 2 other days. 6 of the 10 are institutional flow rows, which arrive in batches on filing days.
No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.
Largest reported share positions in OVID (2026Q2)
| Manager / security | Market value | % portfolio | QoQ |
|---|---|---|---|
| Point72 Asset Management, L.P.CUSIP 690469101 · 2026Q2 | $5.2M | 0.01% | , |
| TWO SIGMA INVESTMENTS, LPCUSIP 690469101 · 2026Q2 | $2.2M | 0.00% | , |
| RENAISSANCE TECHNOLOGIES LLCCUSIP 690469101 · 2026Q2 | $284K | 0.00% | , |
| D. E. Shaw & Co., Inc.CUSIP 690469101 · 2026Q2 | $99K | 0.00% | , |
| MILLENNIUM MANAGEMENT LLCCUSIP 690469101 · 2026Q2 | $87K | 0.00% | , |
Quarterly SEC Form 13F disclosures from the managers Kresmion tracks, not a complete ownership ranking. Non-option holdings only; reported put and call positions are excluded. Different securities are labeled by CUSIP. Values are reporting-period snapshots, not current position values. Filings can arrive up to 45 days after quarter-end.
Recent SEC filings, OVID
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-QSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 8-KSEC EDGAR ↗
- 10-KSEC EDGAR ↗
OVID against its peers
OVID's operating margin of -585.2% ranks in the 38th percentile of 11 Biotechnology sub-industry peers, fiscal periods ending between 2025-12-31 and 2026-06-30.
| Metric | OVID | Peer median | Percentile | n |
|---|---|---|---|---|
| Revenue FY | 7.3M USD | 10.8M USD | 41 | 15 |
| Operating margin | -585.2% | -358.9% | 38 | 11 |
| Net margin | -240.1% | -381.4% | 63 | 11 |
| Return on equity | -13.3% | -58.4% | 89 | 21 |
Peers (22): PRTA, ALLO, ALT, NAUT, AUTL, ASMB, RGNX, MPLT, SPRY, TECX, EPRX, INDP, CYDY, DMAC, ARVN, NGNE, CCCC, MNPR, CBIO, AVTX, RZLT, EDIT. Left out: AGMB (no annual filing), TRXB (no annual filing), EIKN (no annual filing). Fiscal periods ending between 2025-12-31 and 2026-06-30. Every figure is one full fiscal year read from one annual filing (OVID: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.
Related tickers
Follow OVID on a live board
Kresmion is a cross-asset market-intelligence terminal. Open a board scoped to OVID for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.